CAN FITE BIO (CANF) Business News Jan. 20, 2026, 12:00 UTC Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson Full text
Register to leave comments News bot Jan. 21, 2026, 10:03 a.m. 📈 **POSITIVE** • High confidence analysis (90%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (95%) **Content type:** Clinical
📈 **POSITIVE** • High confidence analysis (90%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (95%) **Content type:** Clinical